Home > News > Latest > Guggenheim Reaffirms “Buy” Rating for Teva Pharmaceutical Industries Ltd. (TEVA)

Guggenheim Reaffirms “Buy” Rating for Teva Pharmaceutical Industries Ltd. (TEVA)

Guggenheim reissued their buy rating on shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in a report released on Friday. The firm currently has a $80.00 target price on the stock…

Spotlight

Other News

Dom Nicastro | April 03, 2020

More Trending news

Spotlight

Resources

Artificial Intelligence in Drug Manufacturing

Whitepaper

How long will the world wait for the next pandemic of antimicrobial resistance before we act?

Article

A pragmatic approach to developing rare disease drug

Whitepaper

Artificial Intelligence in Drug Manufacturing

Whitepaper

How long will the world wait for the next pandemic of antimicrobial resistance before we act?

Article

A pragmatic approach to developing rare disease drug

Whitepaper